Effect of nasal inflammation and of intranasal anti-inflammatory treatment on bronchial asthma.
It is logical to look upon the nose and the bronchi as integrated parts of one 'united airway' and we would like to advance the hypothesis that optimal management of airway disease, caused by inhaled allergens, may necessitate control of inflammation in all parts of the airways. Nasal inflammation can aggravate asthma symptoms, and there is a rationale for giving intranasal anti-inflammatory treatment to patients with asthma. (i) Inhaled allergens are predominantly deposited in the nose, whether a patient suffers from rhinitis, asthma or both. (ii) Antigen presentation consequently takes place in the nose, and the response of the airway immune system is thus initiated in the nasal mucous membrane. (iii) Antigen presentation in the nose may possibly induce cell recruitment and activation not only in the nasal mucosa but also in the lower airways. (iv) Suppression of nasal inflammation may therefore be necessary for optimal management of asthma.
Department of Respiratory Diseases, University Hospital of Aarhus, Denmark.
N
N
Mygind
R
R
Dahl
L P
LP
Nielsen
D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000485:Allergens / Q000276:immunology; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000941:Antigens / Q000276:immunology; D001249:Asthma / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D012220:Rhinitis / Q000150:complications* / Q000188:drug therapy / Q000276:immunology
D000305:Adrenal Cortex Hormones; D000485:Allergens; D000893:Anti-Inflammatory Agents; D000941:Antigens; D016207:Cytokines